A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SB-656933 Following 14 Days Repeat Dosing in Healthy Male Smokers.
Latest Information Update: 15 Jul 2023
At a glance
- Drugs Elubrixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GSK
- 25 Feb 2008 New trial record.